OPNT - オピアント・ファ―マシュ―ティカルズ (Opiant Pharmaceuticals Inc.) オピアント・ファ―マシュ―ティカルズ



symbol OPNT
会社名 Opiant Pharmaceuticals Inc (オピアント・ファ―マシュ―ティカルズ)
分野(sector) Basic Industries   素材
産業(industry) Precious Metals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Opiant Pharmaceuticals Inc. formerly Lightlake Therapeutics Inc. is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray a treatment to reverse opioid overdoses which was conceived licensed developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED) a treatment for Bulimia Nervosa (BN) a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.   オピアント・ファ―マシュ―ティカルズは米国の専門製薬会社。主に薬物使用、中毒、摂食障害に対する治療法の開発に従事する。オピオイド系鎮痛剤の過剰摂取をリバ―スさせるナロキソン塩酸塩「NARCAN」鼻腔用スプレ―を開発。同社製品候補には過食症治療薬、コカイン使用障害治療薬、ヘロインワクチンが含まれる。本社所在地はカリフォルニア州サンタ・モニカ。   Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
本社所在地 201 Santa Monica Boulevard Suite 500 Santa Monica CA 90401 USA
代表者氏名 Michael J. Sinclair マイケル・シンクレア
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +1 310-598-5410
設立年月日 38504
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 14人
url www.lightlaketherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/opnt
EBITDA EBITDA(百万ドル) -9.08382
終値(lastsale) 17.27
時価総額(marketcap) 63701206.69
時価総額 時価総額(百万ドル) 58.81564
売上高 売上高(百万ドル) 16.61532
企業価値(EV) 企業価値(EV)(百万ドル) 47.57064
当期純利益 当期純利益(百万ドル) -9.36162
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Opiant Pharmaceuticals Inc revenues totaled $4.9M. Net loss totaled to $10.7M. Results are not comparable due to year end change.



   Opiant, Aptar expand collaboration for the making of Unidose nasal spray for OPNT003  2022/06/08 20:17:32 Seeking Alpha
Opiant Pharmaceuticals (OPNT) on Wednesday said it would expand its long-term collaboration with Aptar Pharma for the making of Aptar''s nasal Unidose device to be used in the production…
   Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene  2022/06/08 20:05:00 GlobeNewswire
Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003 Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003
   Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript  2022/05/14 22:34:06 Seeking Alpha
Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q1 2022 Results Conference Call May 10, 2022 04:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor…
   Inotiv, TScan Therapeutics top healthcare gainers; Opiant, Renovacor lead losers'' pack  2022/05/13 14:07:34 Seeking Alpha
Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%.
   Opiant Pharmaceuticals GAAP EPS of -$2.43 misses by $1.68, revenue of $4.47M misses by $1.43M  2022/05/10 20:09:02 Seeking Alpha
Opiant Pharmaceuticals press release (OPNT): Q1 GAAP EPS of -$2.43 misses by $1.68.Revenue of $4.47M (-30.0% Y/Y) misses by $1.43M.
   Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims  2022/03/21 18:55:00 Kwhen Finance
   Opiant Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation  2022/03/21 11:52:53 Seeking Alpha
   Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q4 2021 Results - Earnings Call Transcript  2022/03/15 23:00:02 Seeking Alpha
   Opiant Pharmaceuticals GAAP EPS of $0.11 beats by $0.01, revenue of $13.8M beats by $0.54M  2022/03/15 20:09:33 Seeking Alpha
Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q4 GAAP EPS of $0.11 beats by $0.01.Revenue of $13.8M (+39.1% Y/Y) beats by $0.54M.
   Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update  2022/03/15 20:05:00 GlobeNewswire
SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021, and provided a corporate update. Recent highlights include:
   Opiant Pharmaceuticals, Inc. to Post FY2021 Earnings of $0.26 Per Share, Oppenheimer Forecasts (NASDAQ:OPNT)  2021/12/15 06:18:42 Transcript Daily
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Oppenheimer issued their FY2021 earnings estimates for shares of Opiant Pharmaceuticals in a research report issued on Wednesday, December 8th. Oppenheimer analyst L. Gershell expects that the technology company will earn $0.26 per share for the year. Oppenheimer has a Outperform rating and a $42.00 price target on the stock. []
   Wells Fargo & Company MN Grows Stock Holdings in Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)  2021/12/12 10:18:42 Dakota Financial News
Wells Fargo & Company MN boosted its holdings in shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) by 0.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 251,007 shares of the technology companys stock after purchasing an additional 925 shares during the []
   Opiant Pharmaceuticals (NASDAQ:OPNT) Earns Outperform Rating from Analysts at Oppenheimer  2021/12/08 21:38:42 Transcript Daily
Investment analysts at Oppenheimer initiated coverage on shares of Opiant Pharmaceuticals (NASDAQ:OPNT) in a research report issued on Wednesday, The Fly reports. The brokerage set an outperform rating on the technology companys stock. NASDAQ OPNT traded up $2.26 on Wednesday, hitting $32.20. 260 shares of the company were exchanged, compared to its average volume of []
   Why U.S. Fentanyl Deaths Will Keep Rising  2021/12/08 19:38:54 RealClearPolitics
Overdose crisis that killed over 100,000 Americans in one year is ''all about fentanyl'', says Roger Crystal of Opiant Pharmaceuticals
   $14.38 Million in Sales Expected for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) This Quarter  2021/12/06 09:40:41 Dakota Financial News
Analysts forecast that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will announce sales of $14.38 million for the current quarter, according to Zacks. Two analysts have made estimates for Opiant Pharmaceuticals earnings, with estimates ranging from $14.15 million to $14.60 million. Opiant Pharmaceuticals posted sales of $9.92 million during the same quarter last year, which would indicate a []

 関連キーワード  (医薬品 米国株 オピアント・ファ―マシュ―ティカルズ OPNT Opiant Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)